
Vincristine Sulphate Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg/10 mL (0.1 mg/mL), 2 mg/10 mL (0.2 mg/mL)
Reference Brands: Oncovin®(US)
Category: Oncology Cancer Care
Vincristine Sulphate Injection is available in Injection and strengths such as 1 mg/10 mL (0.1 mg/mL), 2 mg/10 mL (0.2 mg/mL). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Vincristine Sulphate Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Vincristine Sulphate Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Vincristine Sulphate Injection is a chemotherapy medication used in the treatment of various cancers, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. As a mitotic inhibitor, vincristine works by disrupting cell division, preventing cancer cells from growing and multiplying. In the US, it is marketed under the brand name Oncovin® and is available in various strengths for intravenous administration. In the EU, it is marketed under several brand names, including Vincristine Ebewe. Ideal for B2B pharmaceutical companies looking to expand their oncology product portfolio, this injection is crucial for combination therapy in cancer management globally.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers